Intradural spinal metastases in pediatric patients with primary intracranial neoplasms : Gd-DTPA enhanced MR vs CT myelography

Recently, the application of intravenous gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) has been shown to improve the detection of intradural extramedullary spinal disease in adults. The ability of Gd-DTPA enhanced magnetic resonance (MR) to detect intradural extramedullary spinal metastas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of computer assisted tomography 1990-09, Vol.14 (5), p.730-735
Hauptverfasser: BLEWS, D. E, WANG, H, KUMAR, A. J, ROBB, P. A, PHILLIPS, P. C, BRYAN, R. N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Recently, the application of intravenous gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) has been shown to improve the detection of intradural extramedullary spinal disease in adults. The ability of Gd-DTPA enhanced magnetic resonance (MR) to detect intradural extramedullary spinal metastases was studied in pediatric brain tumor patients. Spinal MR images before and after intravenous injection of Gd-DTPA were analyzed retrospectively in eight pediatric patients with known intracranial neoplasms and clinically suspected subarachnoid tumor seedings. Contrast enhanced spinal MR was compared with CT myelography in four of these patients. In our pediatric population Gd-DTPA enhanced images revealed tumor seeding not appreciable on noncontrast images. Although CT myelography has been the accepted standard investigation in the evaluation of suspected spinal metastases in children, we found that contrast enhanced MR is equal or superior in sensitivity to CT myelography. Spinal MR also provided information not obtainable via CT myelography. In the future, Gd-DTPA enhanced spinal MR should be considered in the initial evaluation of suspected subarachnoid spinal metastases in pediatric patients with known primary brain tumors.
ISSN:0363-8715
1532-3145
DOI:10.1097/00004728-199009000-00009